Cerebral MRI During Sleep
Recent studies in animal models have suggested a critical role for cerebrospinal fluid and Interstitial fluid flux through cerebral parenchyma for removal of byproducts of cellular metabolism and hence in maintaining the health of the brain. This effect is modulated during sleep, suggesting a potentially important mechanism for sleep to maintain both acute homeostasis and long-term cerebral health.
The central goal of these studies is to develop a sensitive MRI biomarker of cerebral conformational changes during sleep. This exploratory work aims to establish the sensitivity and reproducibility of MRI as a non-invasive neuroimaging assessment of cerebral changes during natural sleep and sedation.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Recent studies in animal models have suggested a critical role for cerebrospinal fluid (CSF) / Interstitial fluid (ISF) flux through cerebral parenchyma for removal of byproducts of cellular metabolism and hence in maintaining the health of the brain. It remains unknown to what extent these phenomena exist in the human brain. A key challenge in this work is to make non-invasive and reproducible measurements of the cerebral microenvironment in humans. For these studies, the investigators have implemented a suite of MRI measurements to track physiological changes in the brain during sleep. This exploratory work aims to establish the sensitivity and reproducibility of MRI as a non-invasive neuroimaging assessment of cerebral changes during natural sleep and sedation. The long term goal of this work is to use MRI as an imaging biomarker to assess the cerebral response to normal versus disordered sleep in patients.
Our specific aims will address the following questions:
Aim 1: How sensitive are MRI metrics for determining changes in the brain during sleep?
Aim 2: How reproducible are MRI metrics during sleep and during sedation?
The investigators will recruit 12 normal adult subjects for this study (consecutive respondees to recruitment adverts). The investigators will make regional MRI measurements during onset, maintenance and waking from stage N2 sleep. From these the investigators will characterize which MRI metrics are most sensitive to changes in the cerebral environment, and how these vary for different cerebral regions.
Measurements will be repeated during ~90 minutes of natural sleep, and following oral sedation with 10 mg zaleplon (Sonata).
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
California
-
San Diego, California, United States, 92093-0677
- UC San Diego
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Healthy Adults
Exclusion Criteria:
- age not in range 18-59
- smoking / recreational drug use
- pregnant women / breast feeding
- contraindication to MRI
- contraindications to Zaleplon
- history of cardiovascular pulmonary or cerebral disease (hypertension (diastolic >90 mmHg, systolic > 150 mmHg), unstable cerebrovascular syndromes, prior history of cardiac arrhythmias, unstable angina, chronic obstructive pulmonary disease).
- Current SSRI antidepressant medication
- History of sleep disorder or currently taking sedative / stimulant medication
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cerebral MRI Changes
Time Frame: 90 Minutes of Sleep
|
Change in MRI Signal from Awake Baseline
|
90 Minutes of Sleep
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 170804
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleep
-
NCT03323814CompletedSleep, Slow-wave Sleep, Sleep Enhancement, Sleep Optimization
-
NCT05970276RecruitingSleep | Sleep Quality | Sleep Duration
-
NCT05838339CompletedSleep | Sleep Hygiene | Poor Quality Sleep
-
NCT07409883Not yet recruitingSleep Inertia | Sleep, Slow-wave Sleep, Sleep Enhancement, Sleep Optimization | Night Shift Work
-
NCT05478980CompletedSleep | Mood | Poor Quality Sleep | Good Sleep Habit
-
NCT07149233Enrolling by invitationSleep | Obstructive Sleep Apnea (OSA)
-
NCT06980558CompletedSleep | Surgery | Sleep Quality
-
NCT06990789CompletedSleep Quality | Sleep Perception
-
NCT07577661Not yet recruitingObstructive Sleep Apnea | Sleep-disordered Breathing
-
NCT07200167Not yet recruitingSleep Quality | Sleep Onset Latency
Clinical Trials on Zaleplon
-
NCT07393529RecruitingAdvanced Cancer | Social Networks | Older Adults (65 Years and Older)
-
NCT00878553CompletedSleep Disorder | Primary Insomnia
-
NCT01159652Completed
-
NCT00694317CompletedShort Term Treatment of Insomnia